- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Joe Mclane, Merck
I joined Merck in 1996 as a customer account representative, processing pharmaceutical and vaccine orders for our direct customers.
Joe McLane
Senior Manager, Global Marketing Communications, HPV Franchise, Merck
I joined Merck in 1996 as a customer account representative, processing pharmaceutical and vaccine orders for our direct customers. I wanted to have a career in pharma, and. more importantly, at Merck, because I wanted to be part of something bigger and make a difference. My major accomplishments so far include "Tell Someone," a disease campaign that educated women on the link between cervical cancer and human papillomavirus, and the launch of "One Less," our branded campaign that announced the availability of [HPV vaccine] Gardasil.
Social networks are the new frontier for pharma. Social networks, word-of-mouth initiatives, and other social media will help stimulate conversations. Consumers trust healthcare information they learn in social circles; we are now exploring how to work with these unique networks to further our messages.
In 10 years, I hope to be doing what I love to do with people who are as passionate as I am. I'm trying to convince myself that 40 is the new 30.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
